UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2011

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

 
					
Delaware	 	1-1136	 	22-079-0350	
(State or other jurisdiction
of incorporation)	 	(Commission
File Number)	 	(IRS Employer
Identification No.)	
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

 

Item 5.07. Submission of Matters to a Vote of Security Holders.
(a.) The annual meeting of stockholders (the “Annual Meeting”) of Bristol-Myers Squibb Company (the “Company”) was held on May 3, 2011.
(b.) Stockholders voted on the matters set forth below.
Item 1. The Stockholders elected each of the Company’s 12 nominees to serve as directors of the Company until the 2012 Annual Meeting based upon the following votes:

Name	  	Votes
For	 	  	Votes
Against	 	  	Abstentions	 	  	Broker
Non-Votes	 	
Lamberto Andreotti	  	 	1,148,754,789	  	  	 	9,740,188	  	  	 	4,939,926	  	  	 	293,916,879	  	
Lewis B. Campbell	  	 	1,104,860,075	  	  	 	53,434,687	  	  	 	5,140,141	  	  	 	293,916,879	  	
James M. Cornelius	  	 	1,145,582,169	  	  	 	12,582,419	  	  	 	5,270,315	  	  	 	293,916,879	  	
Louis J. Freeh	  	 	1,045,917,815	  	  	 	105,241,901	  	  	 	12,275,187	  	  	 	293,916,879	  	
Laurie H. Glimcher, M.D.	  	 	1,080,347,589	  	  	 	78,037,356	  	  	 	5,049,958	  	  	 	293,916,879	  	
Michael Grobstein	  	 	1,118,208,899	  	  	 	39,936,408	  	  	 	5,289,596	  	  	 	293,916,879	  	
Leif Johansson	  	 	1,107,180,594	  	  	 	50,975,693	  	  	 	5,278,616	  	  	 	293,916,879	  	
Alan J. Lacy	  	 	1,116,548,476	  	  	 	41,594,085	  	  	 	5,292,342	  	  	 	293,916,879	  	
Vicki L. Sato, Ph.D.	  	 	1,091,181,255	  	  	 	67,156,310	  	  	 	5,097,338	  	  	 	293,916,879	  	
Elliott Sigal, M.D., Ph.D.	  	 	1,148,402,514	  	  	 	9,798,871	  	  	 	5,233,518	  	  	 	293,916,879	  	
Togo D. West, Jr.	  	 	1,115,250,523	  	  	 	42,578,044	  	  	 	5,606,336	  	  	 	293,916,879	  	
R. Sanders Williams, M.D.	  	 	1,097,478,963	  	  	 	60,736,308	  	  	 	5,219,632	  	  	 	293,916,879	  	
Item 2. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for the 2011 year was ratified based upon the following votes:

Votes For	 	 	Votes Against	 	 	Abstentions	 	
 	1,417,820,036	  	 	 	34,327,872	  	 	 	5,203,874	  	
Item 3. The management proposal on the advisory vote on the compensation of our named executive officers was approved based upon the following votes:

Votes For	 	 	Votes Against	 	 	Abstentions	 	 	Broker Non-Votes	 	
 	1,091,146,763	  	 	 	60,179,042	  	 	 	12,109,098	  	 	 	293,916,879	  	
Item 4. The management proposal on the advisory vote on the frequency of the advisory vote on the compensation of our named executive officers received the following votes:

3 Years	 	 	2 Years	 	 	1 Year	 	 	Abstentions	 	 	Broker Non-Votes	 	
 	508,247,522	  	 	 	20,597,353	  	 	 	625,045,481	  	 	 	9,544,547	  	 	 	293,916,879	  	
Item 5. The stockholder proposal on executive compensation disclosure received the following votes:

Votes For	 	 	Votes Against	 	 	Abstentions	 	 	Broker Non-Votes	 	
 	85,828,347	  	 	 	1,068,522,331	  	 	 	9,084,225	  	 	 	293,916,879	  	
Item 6. The stockholder proposal on the stockholder action by written consent received the following votes:

Votes For	 	 	Votes Against	 	 	Abstentions	 	 	Broker Non-Votes	 	
 	444,383,389	  	 	 	705,361,618	  	 	 	13,689,896	  	 	 	293,916,879	  	

Item 7. The stockholder proposal on pharmaceutical price restraint received the following votes:

Votes For	  	Votes Against	  	Abstentions	  	Broker Non-Votes	
33,328,253	  	887,853,921	  	242,252,729	  	293,916,879	
(d.) A majority of the votes cast by stockholders voted, on an advisory basis, to hold an advisory vote on the compensation of our named executive officers every year. The Board of Directors has taken into consideration the views of our stockholders and decided that it will include an advisory stockholder vote on the compensation of our named executive officers in the Company’s proxy materials annually until the next required vote on the frequency of such an advisory vote.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY	
		
By:	 	/s/ Sandra Leung	
Name:	 	Sandra Leung	
Title:	 	General Counsel and Corporate Secretary	
Dated: May 6, 2011